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Abstract 
Ketamine is widely used in veterinary medicine and in medicine. Ketamine is metabolized to its 
active metabolite norketamine principally by liver CYP3A. Drug metabolism alterations during 
aging have severe consequences particularly in anesthesiology and very few studies on older 
animals were conducted for ketamine. The objective of the present study is to assess the influence 
of aging on CYP3A metabolism of ketamine. Liver S9 fractions from 3, 6, 12 and 18 month old 
male Sprague Dawley rats were prepared and Michaelis-Menten parameters were determined for 
primary metabolic pathways. The derived maximum enzyme velocity (i.e. Vmax) suggests a rapid 
saturation of the CYP3A enzyme active sites in liver S9 fractions of 18-month old rats. Observed 
Vmax for Liver S9 fractions from 3, 6 and 12 month old male Sprague Dawley rats were 2.39 
(±0.23), 2.61 (±0.18), and 2.07 (±0.07) respectively compared to 0.68 (±0.02) for Liver S9 
fractions from 18 month old male Sprague Dawley rats. Interestingly, we observed a  6 to 7 fold 
change in the derived Km when comparing Liver S9 fractions from 18 month old male Sprague 
Dawley rats with Liver S9 fractions from younger rats. Our results suggest that rat CYP3A 
enzyme undergoes conformational changes with age particularly in our geriatric group (e.g. 18 
month rats) leading significant decrease in the rate of formation of norketamine. Moreover, our 
results strongly suggest a severe impairment of CYP3A ketamine mediated metabolism.  
 
 
 
 
 
 
 
 3 
Introduction 
In recent years, the improvements in medicine, and life style changes, have increased life 
expectancy and consequently there is a significant increase of geriatric patients needing medical 
and pharmacological treatments. A very large proportion of marketed drugs were not thoroughly 
tested in pediatric and geriatric patients and this has led to numerous medical complications 
[Richardson et al., 2014; Crentsil et al., 2014; Hines, 2013]. Older patients certainly have more 
risks of suffering from adverse drug effects which may be associated with a decreased clearance 
(CL) caused by physiologic changes associated with aging [Meziere et al., 2013; Woodhouse & 
Wynne, 1988]. Additionally, other studies show a significant increase of terminal half-life (T1/2) 
of many drugs related to aging [Iirola et al., 2012; Shi and Klotz, 2011] leading to important 
differences in pharmacokinetic profiles [Veilleux-Lemieux et al., 2013]. Pharmacokinetic and 
drug metabolism alterations during aging have severe consequences particularly in 
anesthesiology [Meziere et al., 2013]. Geriatric surgeries in animal and human are often avoided 
when possible since adverse effects could lead to serious consequences including death.  
Recently, we performed an exhaustive comparison of ketamine and xylazine pharmacokinetics 
and pharmacodynamics using 3, 6, 12 and 18 month old male Sprague Dawley rats and observed 
significant differences in drug exposition (AUC), terminal half-life (T1/2) and clearance (CL) in 
12 and 18 months old rats [Giroux et al., 2015]. Pharmacokinetic parameters (T1/2 and AUC) 
significantly increased and drug CL significantly decreased with aging and these observations 
correlated with physiological results (anesthesia duration, reflexes, cardiac and respiratory 
frequencies and oxygen saturation). As shown in Figure 1, ketamine is metabolized primarily by 
the liver to an active metabolite, norketamine and it is excreted in the urine [Meyer and Fish, 
2008]. In our previous study using rat liver S9 fractions and cDNA CYP3A1 and CYP3A2 
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expressed enzymes, we demonstrated that ketamine is a substrate of CYP3A (i.e. CYP3A1 and 
CYP3A2) [Santamaria et al., 2014]. The significant increase of T1/2 and decrease of CL observed 
in vivo could possibly be associated with hampered CYP450 liver enzymes, which requires 
further investigation.  
The objective of the present study is to assess the influence of aging on CYP3A metabolism of 
ketamine. Liver S9 fractions from 3, 6, 12 and 18 month old male Sprague Dawley rats were 
prepared and Michaelis-Menten parameters were determined for primary metabolic pathways. 
Midazolam, is primarily metabolized in the liver by the CYP3A to its pharmacologic active 
metabolite, α-hydroxymidazolam [Shimizu et al., 2007] and it is a preferred CYP3A substrate 
extensively used for in vitro and in vivo studies [Halama et al., 2013; Mooiman et al., 2013]. 
Midazolam was used to verify and validate CYP3A activity in liver S9 fractions prepared from 
tissues obtained from animals of different age groups. Drug and metabolite analyses were 
performed using a HPLC-MS/SRM method capable of quantifying norketamine and α-
hydroxymidazolam using an isotopic dilution strategy in liver S9 fraction suspensions. 
Materials and Methods 
Chemicals and Reagents 
Ketamine, d4-ketamine, norketamine, d4-norketamine, midazolam, d4-midazolam and α-
hydroxymidazolam and d4- α-hydroxymidazolam were obtained in solution from Cerilliant 
(Round Rock, TX). Other chemicals, including acetonitrile, formic acid, methanol, sodium 
phosphate dibasic and sodium phosphate monobasic were purchased from Fisher Scientific 
(Ottawa, ON, Canada). Commercial rat liver S9 fractions and NADPH regeneration solutions 
were obtained from Corning Gentest (Tewksbury, MA, USA). 
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Animal study 
Twenty-four specific pathogen free male Sprague Dawley rats from Charles River Canada (St-
Constant, QC) were used for this study. Seven to nine weeks old rats (n=6/age group) were 
purchase and kept until they were respectively 3 and 6 months old. Twelve 8 month old rats were 
purchased and kept until they were 12 and 18 months of age (n=6/age group). All rats were 
housed in a standard laboratory animal environment. The rats had ad libidum access to food 
(2018 Teklad Global 18 % Protein Rodent Diet, Harlan Teklad, Bartonville, IL) and reverse 
osmosis water. They were single housed in ventilated cages (Green Line IVC Sealsafe Plus, 
Tecniplast, USA) changed once a week. Rats were housed on corn cob bedding (7097 corncob, 
Harlan Teklad, Bartonville, IL) and they had a high temperature polycarbonate rat retreat 
(Bioserv, Flemington, NJ) and one nylabone (Bioserv, Flemington, NJ) for environmental 
enrichment. The Institutional Animal Care and Use Committee approved the protocol prior to 
animal use in agreement with the guidelines of the Canadian Council on Animal Care [Canadian 
Council on Animal Care, 1993]. Rats were euthanized with CO2, livers were rapidly remove and 
S9 fractions where prepared. 
Rat Liver S9 preparation and incubation 
For each age group, three livers were pooled and homogenized in a 50 mM TRIS-HCl buffer, pH 
7.4, containing 150 mM KCl and 2 mM EDTA at a ratio of 1:4 (w:v). The homogenates were 
centrifuged at 9,000 g for 20 minutes. The total amount of protein in each supernatant was 
determined using the standard Coomassie protein assay (Bradford). Supernatant aliquots were 
kept à -80 °C until usage.  
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The incubations were performed as previously described [Lavoie et al., 2013; Santamaria et al. 
2014] and were performed minimally in triplicate. The incubations were performed in a 
microcentrifuge tube and contained various concentrations ranging from 1 to 100 µM of 
ketamine or midazolam, 0.5 mg/mL of S9 fraction proteins diluted in 100 mM phosphate buffer, 
pH 7.4. Liver S9 enzyme suspensions (total volume of 100 µL) were fortified with 5 µL of 
NADPH-regenerating solution A (Corning BD Biosciences Cat. No. 451220) and 1 µL of 
solution B (Corning BD Biosciences Cat. No. 451200) and preincubated at 37°C for 5 min prior 
the addition of  ketamine or midazolam. For the determination of Km and Vmax, the concentration 
of norketamine or α-hydroxymidazolam was determined after 10 min incubation to calculate the 
initial rate of formation (i.e. Vi). Fifty µL of samples were taken and mixed with 250 µL of the 
deuterated internal standard solution (1 µM d4-norketamine or d4-α-hydroxymidazolam in 
acetonitrile) in a 1.5 mL centrifuge tube. Samples were centrifuged at 12,000 g for 10 min and 
200 µL of the supernatant was transferred into an injection vial for HPLC-MS/SRM analysis.  
Quantitative Analytical Methods 
The concentrations of norketamine and α-hydroxymidazolam were determined using an HPLC-
MS/SRM assay. Two µL samples were injected using a Thermo Scientific Accela HPLC System 
(San Jose, CA, USA) onto a Thermo Hypersil Phenyl 100 x 2 mm column (5µm) with flow rate 
of 300 µL/min. The mobile phase consisted of a mixture of acetonitrile, methanol, water and 
formic acid at a ratio of 60:20:20:0.1, respectively. The Thermo Scientific linear ion trap mass 
spectrometer (Thermo LTQ-XL) was interfaced with the HPLC system using a pneumatic 
assisted electrospray ion source. The mass spectrometer was coupled with the HPLC system 
using a pneumatically assisted electrospray ion source (ESI). The sheath gas was set to 25 units 
and the ESI electrode was set to 4000 V in positive mode. The capillary temperature was set at 
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300 °C, the capillary voltage to 15 V and the collision energy was set to 40%. All scan events 
were acquired with a 100 msec maximum injection time. Metabolites and corresponding 
deuterium-labeled molecule analogues were analyzed in full scan MS/MS and the quantification 
was based on specific post-processing SRM extracted ion chromatograms. The selected reaction 
monitoring (SRM) transitions were set to m/z 224.1 → 179.0, 228.1 → 183.0, 342.1 → 297.0 and 
346.1 → 301.0 for norketamine, d4-norketamine, α-hydroxymidazolam and d4-α-
hydroxymidazolam  respectively. The analytical range used was ranging from 0.05µM to 50 µM.  
Data analysis and regression 
All non-linear regression analyses were performed with PRISM (6.0f) GraphPad software (La 
Jolla, CA) using the non-linear curve-fitting module with an estimation of the goodness of fit.  
The Michaelis-Menten equation describes the rates of irreversible enzymatic reactions that are 
generally observed for CYP mediated metabolic reactions. Michaelis-Menten parameters can be 
estimated with non-linear regression analysis using the Michaelis-Menten equation [Michaelis 
and Menten, 1913].  
𝑣" = $%&'	[*],%-	[*]  (1) 
Were the initial velocity (vi) was determined using equation 2. 
𝑣" = .[/].0 = [1234567849:5;<7=;9]>?	%@ABC	D"E 	𝑜𝑟	 [EHIJK0LD"EK]>?	%@ABC	D"E  (2) 
The initial rate (vi) was calculated based on the concentration of norketamine or α-
hydroxymidazolam measured after a 10 minutes incubation of ketamine or midazolam in rat liver 
S9 enzyme suspensions. Additionally, the enzyme-mediated clearance (CLuint) that would occur 
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without physiological limitations including protein binding or hepatic blood flow was determined 
using equation (5). 
𝐶𝐿𝑢"E0 = P%&',%  (5) 
Statistical analysis 
Results are presented as means (± SD). The statistical difference was assessed with a one-way 
ANOVA and a Tukey's multiple comparisons test using GraphPad PRISM (version 6.0f); p < 
0.05 was considered significant.  
Results and Discussion 
In our previous study, an intraperitoneal administration of ketamine (80 mg/kg) and xylazine (10 
mg/kg) in male Sprague Dawley rats of 3, 6, 12 and 18 months of age (n=6/age group) caused a 
significant increase of the AUC0-t and AUC0-∞ with aging [Giroux et al., 2015]. Compared to 3 
month old rats, the ketamine exposure (AUC0-t) increased up to a factor of 4.15 compared with 18 
month old rats. The elimination half-life (T1/2) and relative clearance (CL/F) significantly 
decreased with aging. The decrease in T1/2 and CL/F might be explained by an age-associated 
reduction in renal function or an increase in volume of distribution of lipid soluble drugs resulting 
in a prolongation of T1/2 but we can't exclude hepatic clearance impairments. Ketamine is 
metabolized primarily by the liver CYP3A [Santamaria et al., 2014; Mössner et al. 2011] (i.e. 
CYP3A1 and CYP3A2) to its active metabolite norketamine. Alterations in liver metabolism (e.g. 
hepatic clearance) with aging could explain the higher AUC observed in the aging rats. Moreover, 
selected organs, including liver, were taken for histopathology to confirm tissue integrity with 
aging. 
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The effect of substrate concentration on the initial rate (Vi) of an enzyme-catalyzed reaction is a 
fundamental concept in enzyme kinetics. Km is an indicator of the affinity that an enzyme has for 
a particular substrate, hence the thermodynamic stability of the enzyme-substrate complex. The 
stability of the enzyme-substrate complex is closely related to primary, secondary and tertiary 
structures of the enzyme. It plays a central role in defining the energetically favored binding 
cluster of the substrate into the active enzyme site [Sun and Scott, 2010]. As shown in silico, the 
structure of the binding cluster may lead to different metabolites or affect the rate of formation 
[Sun and Scott, 2010]. To adequately determine the value of the apparent Michaelis-Menten 
constant Km as well as the maximum rate achieved by the system (Vmax), the data were fitted with 
the Michaelis-Menten equation (1). The initial rate (Vi) was calculated using the equation (2) and 
concentrations of α-hydroxymidazolam or norketamine were determined after 10 min midazolam 
or ketamine incubation in rat liver S9 fraction suspensions by HPLC-MS/SRM. Figure 2 shows 
results coherent with a kinetics following a Michaelis-Menten enzymatic reaction for all rat liver 
S9 fractions from all age groups and data were compatible with commercial rat liver S9 fractions 
(data not shown). The derived data are presented in Table 1. Midazolam is a well-characterized 
substrate of CYP3A and the primary biotransformation product is α-hydroxymidazolam. As 
illustrated in Table 1 and Figure 2, the observed Km values were not significantly different when 
comparing age groups. This is interesting because it suggest that enzyme-substrate complex 
structure was not significantly different between midazolam and CYP3A (i.e. CYP3A1 and 
CYP3A2) with age. However, the derived Vmax suggest a rapid saturation of the CYP3A enzyme 
active sites in liver S9 fractions of 18-month old rats, thus affecting significantly the intrinsic 
clearance (CLuint) of the drug. Interestingly for ketamine, the derived Km value significantly 
changed in geriatric rats. This observation is very distinctive compared to rat liver CYP3A 
mediated metabolism of midazolam. The Km value is directly related to the thermodynamic 
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stability of the binding cluster of ketamine in the active site of CYP3A. The data indicates a 
significant decrease of Km in liver S9 fractions of 18-month old rats and suggest that ketamine 
may have stronger interactions with CYP3A active site residues leading to a more 
thermodynamically stable enzyme-substrate complex. However it may also suggest that the 
enzyme binds the substrate more tightly and consequently necessitates more energy to form the 
activated transition state complex (EX‡), a necessary intermediate to form the enzyme-product 
complex (EP) as shown in Equation 6. 
      (6) 
Free energy difference associated with the formation of the enzyme-substrate complex (ΔGbinding) 
can have a significant impact on the observed Km but an increase of the ΔG‡ (difference of free 
energy between EX‡ and ES) can also significantly decrease the rate constant kcat (i.e. turnover 
number) witch represents the number of substrate molecules each enzyme site can convert to a 
metabolite per unit of time. The rate constant kcat can be related to Vmax using the Equation 7. 
𝑉DLR = 𝑘TL0× 𝐸0H0LW  (7) 
As illustrated in Figure 2 and in Table 1, derived Vmax values shows significant differences with 
age specifically when comparing with results obtain from liver S9 fractions of 18-month old rats. 
A decrease of Vmax suggest a rapid saturation of the CYP3A enzyme active sites similar to what 
has been observed with the reference CYP3A substrate midazolam. These results are therefore 
compatible with the formation of a more stable enzyme-substrate complex (ES) but a less 
favorable transition state complex (EX‡) leading to an increase of ΔG‡, thus a decrease of kcat and 
Vmax. Conformational change of the CYP3A active site with age can potentially explain these 
results and protein misfolding is characteristic of several age-related problems. The interaction of 
E + S           ES             EX‡                  EP             E + P
kcat
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the active site residues is substrate dependent and the results appear to suggest that an 
energetically favored binding cluster of ketamine in the active site of CYP3A is observed with 
age but interestingly this effect was not observed for midazolam. The formation of a more stable 
enzyme-substrate complex (ES) may have severe consequences on drug-drug interactions, a 
major issue in geriatric populations. Equation 5 was used to calculate the CLuint, and the observed 
CLuint diminishes with aging, associated to the midazolam CYP3A catalyzed reaction, but 
increases for ketamine (Table 1). When using equation 5, the calculation of CLuint assumes that 
the concentration of the enzyme catalytic sites remain constant. This assumption cannot be made 
if conformational changes of the CYP3A active site occurs with aging. Consequently, the CLuint 
cannot be compared between age groups for the ketamine CYP3A mediated reaction. As shown 
in Figure 2, the rate of formation of norketamine undergoes a very rapid saturation in the liver S9 
fractions of 18-month old rats suggesting that following a relatively high ketamine dose (80 
mg/kg), drug metabolism is impaired leading to a significant increase of drug exposition (AUC) 
and elimination. These results are in accordance with our recent in vivo investigation [Giroux et 
al., 2015].    
Conclusion 
Age and related factors have a substantial effect on ketamine bioavailability that can be related to 
physiological changes but also to liver metabolism alterations. Our results suggest that rat 
CYP3A enzyme undergoes conformational changes with age particularly in our geriatric group 
(e.g. 18 month rats) leading to significant decrease in the rate of formation of norketamine. 
Moreover, results strongly suggest a severe impairment of CYP3A ketamine mediated 
metabolism.  
 
 12 
Acknowledgments 
This project was funded by the National Sciences and Engineering Research Council of Canada 
(F.Beaudry discovery grant no. 386637-2010). The HPLC-MS/MS analyses were performed on 
instruments funded by the National Sciences and Engineering Research Council of Canada 
(F.Beaudry Research Tools and Instruments Grants no. 439748-2013). R. Santamaria received a 
scholarship from Le Fond du Centenaire (Faculté de médecine vétérinaire, Université de 
Montréal). The animal study was funded by CALAM/CALAS (P. Vachon 2014 research fund). 
Authorship Contributions 
Each author's contributions to the manuscript are the following; 
Participated in research design: Santamaria R, Vachon P, Beaudry F 
Conducted experiments: Santamaria R, Giroux MC, Vachon P, Beaudry F 
Performed data analysis: Santamaria R, Beaudry F 
Wrote or contributed to the writing of the manuscript: Santamaria R, Vachon P, Beaudry F 
All authors: No reported conflicts of interest. The research was funded by recognized Canadian 
research funding agencies.     
 13 
References 
Canadian Council on Animal Care (1993). Guide to the care and use of experimental animals, vol 
1, 2nd ed. Ottawa (Canada): Canadian Council on Animal Care 
Crentsil V, Lee J, Jackson A (2014). Quantitative drug benefit-risk assessment: utility of 
modeling and simulation to optimize drug safety in older adults. Ann Pharmacother. 48(3):306-
313. 
Giroux MC, Beaudry F, Santamaria R, Hélie P, Burns P, and Vachon P (2015), Physiological, 
biochemical and pharmacokinetic comparisons between 3, 6, 12 and 18 month old male Sprague 
Dawley rats following ketamine-xylazine anesthesia, BMC Veterinary Research. MS ID : 
9382132761532116. In Press 
Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE (2013). A nanogram dose of 
the CYP3A probe substrate midazolam to evaluate drug interactions. Clinical Pharmacology and 
Therapeutics. 93(6):564-571. 
Hines RN (2013). Developmental expression of drug metabolizing enzymes: impact on 
disposition in neonates and young children. Int J Pharm. 452(1-2):3-7.  
Iirola T, Ihmsen H, Laitio R, Kentala E, Aantaa R, Kurvinen JP, Scheinin M, Schwilden H, 
Schüttler J, Olkkola KT. Population pharmacokinetics of dexmedetomidine during long-term 
sedation in intensive care patients. Br J Anaesth. 108(3):460-468. 
Lavoie DS, Pailleux F, Vachon P, Beaudry F (2013). Characterization of xylazine metabolism in 
rat liver microsomes using liquid chromatography-hybrid triple quadrupole-linear ion trap-mass 
spectrometry. Biomed Chromatogr. 27(7):882-888 
Meyer RE, Fish RE (2008). Pharmacology of injectable anesthetics, sedatives, and tranquilizers, 
Anesthesia and Analgesia in Laboratory Animals. 2nd ed. San Diego, (CA): Academic Press. p. 
27-82. 
Meziere A, Paillaud E, Plaud B (2013). Anesthesia in the elderly. Presse Med, 42(2), 197-201.  
Michaelis L and Menten ML (1913). Die Kinetik der Invertinwir‐ kung. Biochemische Zeitschrift 
49:334-336. 
Mooiman KD, Maas-Bakker RF, Rosing H, Beijnen JH, Schellens JH, Meijerman I (2013). 
Development and validation of a LC-MS/MS method for the in vitro analysis of 1-
hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition 
in complex matrix mixtures. Biomedical Chromatography. 27(9):1107-1116. 
Mössner LD, Schmitz A, Theurillat R, Thormann W, Mevissen M (2011). Inhibition of 
cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and 
specific cytochrome P450 enzymes from horses, dogs, and humans. American Journal of 
Veterinary Research. 72(11):1505-1513. 
 
 14 
Richardson K, Bennett K and Kenny RA (2014). Polypharmacy including falls risk-increasing 
medications and subsequent falls in community-dwelling middle-aged and older adults. Age 
Ageing. afu141 (Epub ahead of print) 
Santamaria R, Pailleux F, Beaudry F (2014). In vitro ketamine CYP3A-mediated metabolism 
study using mammalian liver S9 fractions, cDNA expressed enzymes and liquid chromatography 
tandem mass spectrometry. Biomed Chromatogr. 28(12):1660-1669 
Shi S, Klotz U (2011), Age-related changes in pharmacokinetics. Curr Drug Metab. 12(7):601-10. 
Shimizu M, Uno T, Tamura HO, Kanazawa H, Murakami I, Sugawara K, Tateishi T (2007). A 
developed determination of midazolam and 1'-hydroxymidazolam in plasma by liquid 
chromatography-mass spectrometry: application of human pharmacokinetic study for 
measurement of CYP3A activity. Journal of Chromatography B. 847(2):275-281. 
Sun H, Scott DO (2010). Structure-based drug metabolism predictions for drug design. Chem 
Biol Drug Des. 75:3-17 
Veilleux-Lemieux D, Castel A, Carrier D, Beaudry F, Vachon P (2013), Pharmacokinetics of 
ketamine and xylazine in young and old Sprague-Dawley rats. J Am Assoc Lab Anim Sci. 
52(5):567-70 
  
 15 
Table 1. Kinetic parameters associated with the formation α-hydroxymidazolam and  
norketamine in liver S9 fractions from aging rats. 
α-hydroxymidazolam Vmax 
nmol min-1 mg-1 
Km 
 µM (nmol mL-1) 
CLuint 
mL min-1 
3 month liver S9 fractions 0.247 (± 0.017) 4.32 (± 0.26) 0.057 
6 month liver S9 fractions 0.264 (± 0.021) 6.22 (± 0.99) 0.042 
12 month liver S9 fractions 0.216 (± 0.020) 4.18 (± 0.05) 0.052 
18 month liver S9 fractions 0.0398 (±0.003)1 3.76 (± 1.45)3 0.011 
norketamine    
3 month liver S9 fractions 2.39 (± 0.23) 15.99 (± 4.28) 0.150 
6 month liver S9 fractions 2.61 (± 0.18) 18.38 (± 3.85) 0.142 
12 month liver S9 fractions 2.07 (± 0.073) 19.04 (± 0.94) 0.109 
18 month liver S9 fractions 0.68 ( 0.02)2 2.65 (± 0.49)4 0.256 
 
1,2, p < 0.001 
3 p > 0.05 
4 p < 0.05  
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Figure legends 
 
Figure 1. Molecular structures of ketamine, norketamine, midazolam and α-hydroxymidazolam 
 
Figure 2. Determination of Michaelis constant Km and maximum velocity Vmax using non-linear 
regression fitting. Each point represents the mean (±SD) of experiments in triplicate. Significant 
differences of the initial rate of formation (Vi) where observed starting at 5µM substrate 
concentration for liver S9 fractions of 18-month old rats. 
* p < 0.05 
** p < 0.01 
**** p < 0.0001 
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Figure 1. 
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Figure 2. 
 
